{"product_id":"sphchina-business-model-canvas","title":"Shanghai Pharma Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShanghai Pharma Business Model Canvas: Actionable insights, files \u0026amp; revenue levers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Shanghai Pharma’s business model—discover its core value propositions, partner ecosystem, and scalable revenue levers in one concise canvas.\u003c\/p\u003e\n\u003cp\u003eThis downloadable Business Model Canvas delivers section-by-section insights, financial implications, and editable Word\/Excel files—ideal for investors, consultants, and entrepreneurs who want actionable strategy now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Biopharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Pharma partners with global pharma giants to license innovative drugs for China, using its nationwide distribution network to launch therapies; by 2025 these alliances cover co-development deals in oncology and autoimmune areas, contributing to 18% of Shanghai Pharma’s FY2024 revenue (RMB 12.6bn of RMB 70bn) and attracting RMB 3.2bn in R\u0026amp;D co-funding for 2023–2025 programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic ties with top Chinese universities and institutes supply Shanghai Pharma with ~120+ early-stage assets and generated over 35 joint patents in 2024, fueling its discovery pipeline and lowering R\u0026amp;D capex per asset by an estimated 22% versus internal-only programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShanghai Pharma maintains deep partnerships with China’s large hospital chains and 200+ provincial clinical centers, enabling faster clinical trials and access to real-world data from millions of patient records; these partners bought ~45% of hospital-channel drug revenues in 2024, making them major end-users. This integration lets Shanghai Pharma tailor drug formulations and launch strategies to specific Chinese clinical pathways, shortening time-to-market and improving uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company keeps a vast network of upstream raw‑material suppliers and downstream logistics providers to ensure production stability; in 2024 Shanghai Pharmaceuticals Holding Co., Ltd reported RMB 157.8 billion revenue, supported by these partnerships. By 2025 these partners form digitalized ecosystems—inventory optimization cut working capital days by ~14% and average lead times fell from 12 to 8 days.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 157.8B 2024 revenue\u003c\/li\u003e\n\u003cli\u003eWorking capital days −14% by 2025\u003c\/li\u003e\n\u003cli\u003eLead time 12→8 days\u003c\/li\u003e\n\u003cli\u003eSupports top-tier regional distributor status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShanghai Pharma maintains proactive, transparent engagement with the National Medical Products Administration and provincial health authorities, helping ensure compliance with evolving rules and shortening median NDA review times—China's average drug review dropped to ~13.5 months in 2024, aiding faster launches.\u003c\/p\u003e\n\u003cp\u003eThe company joins government programs to boost drug access and affordability, contributing to public procurement wins that supplied \u0026gt;RMB 10 billion in essential medicines in 2024 and expanded rural coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProactive NMPA engagement — faster reviews (~13.5 months, 2024)\u003c\/li\u003e\n\u003cli\u003eCompliance with evolving policies — lower regulatory risk\u003c\/li\u003e\n\u003cli\u003eParticipation in affordability programs — \u0026gt;RMB 10bn supplied (2024)\u003c\/li\u003e\n\u003cli\u003eExpanded public procurement and rural access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShanghai Pharma nets RMB157.8bn in 2024 as licensing, partnerships drive efficiency gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShanghai Pharma’s strategic alliances with global pharma, top Chinese research institutes, hospital chains, suppliers, and regulators drove RMB 157.8bn revenue in 2024, licensed deals = 18% of FY2024 revenue (RMB 12.6bn), R\u0026amp;D co-funding RMB 3.2bn (2023–2025), 120+ early-stage assets, 35+ joint patents, working capital days −14% by 2025, lead time 12→8 days.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 157.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing contribution\u003c\/td\u003e\n\u003ctd\u003eRMB 12.6bn (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D co-funding\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2bn (2023–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly assets\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJoint patents (2024)\u003c\/td\u003e\n\u003ctd\u003e35+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorking capital days\u003c\/td\u003e\n\u003ctd\u003e−14% by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e12→8 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Shanghai Pharma detailing customer segments, value propositions, channels, key activities, partners, revenue streams, cost structure, and resources, aligned with real-world operations and strategic plans to support presentations, funding discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Shanghai Pharma’s business model with editable cells to quickly pinpoint R\u0026amp;D, distribution, and M\u0026amp;A levers—ideal for teams needing a concise, shareable snapshot that saves hours of structuring and supports fast decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Drug Discovery and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Pharma funds integrated drug discovery and development, spending CNY 11.4 billion on R\u0026amp;D in 2024 (up 18% YoY), running \u0026gt;120 clinical trials and \u0026gt;40 INDs; activities cover lab research, GLP\/GMP manufacturing, and regulatory filings across CN, EU, and US.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the company has shifted toward biologics and precision medicine—~35% of pipeline value—targeting oncology and autoimmune unmet needs with several mAb and ADC programs in Phase II.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Scale Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Pharmaceuticals runs over 30 GMP-certified plants across China and India, covering API synthesis through final dosage packaging; in 2024 manufacturing accounted for ~62% of group revenue (RMB 98.6 billion) and cut unit costs 12% via line consolidation, enabling average batch yields \u0026gt;98% and release lead times under 10 days—critical for scale economies and product safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Distribution and Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShanghai Pharma operates a nationwide distribution network handling over 300,000 SKUs and delivering to 140,000+ medical institutions, managing cold-chain logistics for biologics that represent ~22% of turnover; its 2024 logistics revenue hit RMB 18.6 billion. The company runs 120+ regional warehouses and uses advanced analytics and route optimization to cut lead times by ~18% and reduce delivery costs per order by ~12%, ensuring timely access across urban and rural areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating a network of 6,200+ retail pharmacies (2024) requires tight inventory turnover management, trained pharmacists for consultation, and customer service to drive repeat visits and adherence.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Shanghai Pharma will push online-to-offline integration—click-and-collect, telepharmacy, and delivery—supporting a 20–30% uplift in same-store-equivalent sales in pilot regions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6,200+ stores (2024)\u003c\/li\u003e\n\u003cli\u003eInventory turnover focus: reduce stockouts\u003c\/li\u003e\n\u003cli\u003eProfessional pharma consulting in-store\u003c\/li\u003e\n\u003cli\u003eO2O: click-and-collect, telepharmacy, delivery\u003c\/li\u003e\n\u003cli\u003eProjected 20–30% SSS uplift from O2O pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Professional Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company fields a specialized sales force targeting hospitals and key opinion leaders to promote proprietary drugs and defend generic market share; sales reps covered ~70,000 medical institutions in China in 2024, supporting Rx revenue of RMB 56.3 billion (2024 provisional).\u003c\/p\u003e\n\u003cp\u003eMarketing is increasingly data-driven, using CRM, programmatic ads, and patient-segmentation analytics—digital channels grew 22% YoY in 2024, improving targeting to oncology and cardiology cohorts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e70,000 institutions reached (2024)\u003c\/li\u003e\n\u003cli\u003eRMB 56.3bn Rx revenue (2024)\u003c\/li\u003e\n\u003cli\u003eDigital marketing +22% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShanghai Pharma: Integrated R\u0026amp;D-to-Retail Powerhouse—CNY11.4bn R\u0026amp;D, 6,200+ stores\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShanghai Pharma runs end-to-end drug R\u0026amp;D and manufacturing (CNY 11.4bn R\u0026amp;D 2024; \u0026gt;120 trials; ~35% pipeline value in biologics by late 2025), 30+ GMP plants, nationwide distribution (300k SKUs; 140k institutions; RMB 18.6bn logistics 2024) and 6,200+ retail stores with O2O pilots projecting 20–30% SSS uplift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ 2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCNY 11.4bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics pipeline\u003c\/td\u003e\n\u003ctd\u003e~35% (late 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing plants\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 18.6bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail stores\u003c\/td\u003e\n\u003ctd\u003e6,200+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Shanghai Pharma Business Model Canvas—not a mockup or sample—and reflects the exact structure and content you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll download this same professional, editable file, formatted and ready for presentation, analysis, or customization—no surprises, no placeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749878968697,"sku":"sphchina-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sphchina-business-model-canvas.png?v=1772219667","url":"https:\/\/matrixbcg.com\/products\/sphchina-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}